A significant rise in gluten intolerance diagnoses around the world is driving the market for treatments, expected to reach $2.5 billion by 2034, as consumer demand for gluten-free options surges.
Rising Rates of Gluten Intolerance Fuel Market Expansion
Wilmington, Del. — July 22, 2024 – There is a substantial increase in the diagnosis of gluten intolerance and celiac disease around the globe, driving a growing market for related treatments. The market, which was valued at $593.5 million in 2023, is expected to escalate at a compound annual growth rate (CAGR) of 13.9% from 2024 to 2034, reaching $2.5 billion by 2034.
Market Drivers
The acceleration in market growth is largely attributed to heightened consumer demand for gluten-free foods and beverages, providing individuals with more dietary choices. Continuous innovation in creating gluten-free products that are tastier, have better texture, and offer higher nutritional value is reinforcing the market’s expansion. Additionally, this trend is making a gluten-free diet more sustainable and appealing for those who need it.
Furthermore, personalized treatment plans and precision medicine, which cater to individual genetic profiles, are enhancing the efficacy of gluten intolerance treatments. E-commerce and online retail platforms are also broadening the accessibility of gluten-free products, contributing to market growth.
Investment and Innovation
A significant investment is being funneled into developing new pharmaceutical treatments. This includes enzyme supplements that break down gluten and drugs aimed at modifying immune responses. These innovations hold promise for offering effective management for those affected by gluten intolerance.
Advancements in biotechnology are on the horizon as well, with genetically modified grains that could be safe for gluten-intolerant individuals. The growing availability of gluten-free options in dining establishments is also making it easier for individuals to adhere to their dietary requirements, thus boosting market demand.
Key Trends and Research
Research into non-dietary therapies such as vaccines, probiotics, and microbiome therapies could provide alternative treatment pathways, further expanding the market. Additionally, consumers are pushing for transparency regarding ingredients and product quality in gluten-free foods, prompting manufacturers to enhance their offerings.
Improvements in food technology are also noteworthy, with better gluten substitutes and refined manufacturing processes improving the overall quality and diversity of gluten-free products. Leveraging artificial intelligence to predict and diagnose gluten intolerance can lead to earlier interventions and more effective management, which, in turn, supports market growth.
Market Segmentation
The market segmentation of gluten intolerance treatment includes diverse drug types, such as antihistamines and epinephrine. Antihistamines, in particular, play a crucial role in managing allergic reactions related to gluten intolerance, such as itching, rash, and swelling. The growing diagnostic capabilities for gluten intolerance are increasing the demand for these medications.
Regarding indications, the segment for celiac disease is expected to see significant growth, driven by heightened awareness and enhanced diagnostic techniques.
Regional Outlook
North America remains a key market due to its high prevalence of celiac disease and gluten sensitivity. Increased awareness and diagnostic rates in the region are driving the demand for treatments. Improved healthcare infrastructure and growing awareness among both healthcare providers and the public are contributing to this trend.
In the Asia Pacific, changing global dietary trends, increasing health consciousness, and rising disposable incomes are influencing market growth. Investments in healthcare infrastructure are improving access to diagnostic and treatment facilities for gastrointestinal disorders, including gluten intolerance.
Key Players
The competitive landscape of the gluten intolerance treatment market includes a mix of pharmaceutical and biotechnology firms, as well as food manufacturers and specialty product providers. Companies like Precigen ActoBio, Calypso Biotech SA, and Alvine Pharmaceuticals Inc. are notable participants in this sector.
Notably, in 2023, Amgen filed a patent for a treatment method for celiac disease using an antigen-binding fragment or an anti-IL-15 antibody, underlining the ongoing innovation in the field.
As awareness and diagnosis of gluten intolerance continue to rise, driven by advancements in food and medical technologies, the market for gluten intolerance treatments is poised for substantial growth in the coming decade.